(29 days)
Not Found
No
The summary describes a calibration material for an immunoassay analyzer and does not mention any AI or ML components.
No
The device is described as a calibrator used for the verification of calibration of a reagent for immunoassay analyzers, not for treating any specific disease or condition.
No
This device is used for the verification of calibration of a reagent, not for diagnosing a patient's condition. It serves as a quality control material for an immunoassay analyzer.
No
The device description explicitly states it is a "lyophilized product consisting of synthetic Estradiol in a human serum matrix," indicating it is a physical reagent, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's "For use in the verification of the calibration established by the Elecsys Estradiol III reagent on the indicated Electys and cobas e immunoassay analyzers." This indicates it's used in vitro (outside the body) to assess the performance of another diagnostic test (the Elecsys Estradiol III reagent).
- Device Description: The description mentions it's a "lyophilized product consisting of synthetic Estradiol in a human serum matrix." This is a common format for calibrators and controls used in in vitro diagnostic assays.
- Function: The device is used to "verify the calibration" of a diagnostic test. Calibrators and controls are essential components of in vitro diagnostic systems to ensure accurate and reliable results.
While the document doesn't explicitly use the term "IVD," the intended use and description clearly align with the definition of an In Vitro Diagnostic device. It's a product used in vitro to assess the performance of a diagnostic test that measures a substance in a human sample.
N/A
Intended Use / Indications for Use
For use in the verification of the callbration established by the Elecsys Estradiol III reagent on the indicated Electys and cobas e immunoassay analyzers.
Product codes (comma separated list FDA assigned to the subject device)
JJX
Device Description
The Elecsys Estradiol III CalCheck is a lyophilized product consisting of synthetic Estradiol in a human serum matrix. It has been standardized against CRM6004a via ID-GC/MS (isotope dilution gas chromatography mass spectrometry).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Two studies were performed in order to verify the stability claims for the Elecsys Estradiol III CalCheck: Study 1. Open-Vial Stability and Study 2. Accelerated Stability.
Study 1. Open-Vial Stability:
The on-test and reference materials were tested in duplicate. The on-test material was reconstituted and stored for 6 hours at 25℃ (in an open vial). The reference material was a freshly reconstituted set of CalChecks. The on-test recovery was calculated as a percent of the reference value. One Estradiol III CalCheck lot was evaluated in duplicate on the cobas e 411. The data support the package insert claim that reconstituted Estradiol III CalCheck is stable up to 4 hours at 20-25°C.
Study 2. Accelerated Stability:
The on-test material was stored lyophilized (as supplied to the user) at 35°C for 3 weeks. The reference material was a freshly reconstituted set of CalChecks (stored at 2-8℃). After 3 weeks, the test and reference materials were tested in duplicate. The on-test recovery was calculated as a percent of the reference value. One Estradiol III CalCheck lot was evaluated in duplicate on the cobas e 411. The accelerated stability model employed supports an initial shelf-life claim of 18 months when the Estradiol III CalCheck are stored under normal storage conditions of 2-8°C. Real-time stability studies are ongoing.
Value assignment testing was conducted for each Elecsys Estradiol III CalCheck lot manufactured. The CalChecks are run in duplicate on at least three cobas e 601/MODULAR ANALYTICS E170 analyzers. The assigned value of each CalCheck is defined as the mean value obtained over at least 6 determinations (duplicate runs on at least 3 analyzers) of the respective CalCheck. The CalCheck assigned range is calculated as ±27% of the assigned value for all levels (1, 2 and 3). The same value assignment procedure is performed on the cobas e 411/Elecsys 2010. The assigned values obtained are compared to those obtained on the cobas e 601. The mean value obtained on the additional analyzer must be within 10% of the master platform assigned value. After this acceptance criterion is met, the assigned values from the master platform are deemed valid for the MODULAR ANALYTICS E170, Elecsys 2010, cobas e 411, cobas e 601, and cobas e 602 immunoassay analyzers.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Study 1 (Open-Vial Stability) acceptance criterion: CalCheck Level 1 is 85-115% recovery; and for CalCheck Levels 2-3, the acceptance criterion is recovery of 90-110% recovery of the reference material value.
Study 2 (Accelerated Stability) acceptance criterion: CalCheck Level 1 is 85-115% recovery; and for CalCheck Levels 2-3, the acceptance criterion is recovery of 90-110% of the reference material value.
Value Assignment: The CalCheck assigned range is calculated as ±27% of the assigned value for all levels (1, 2 and 3). The mean value obtained on additional analyzer must be within 10% of the master platform assigned value.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles a stylized caduceus, featuring a staff with three intertwined snakes and a pair of wings at the top.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
ROCHE DIAGNOSTICS KELLI TURNER REGULATORY AFFAIRS PRINCIPAL 9115 HAGUE ROAD INDIANAPOLIS IN 46250
December 16, 2014
Re: K143284
Trade/Device Name: Elecsys Estradiol III CalCheck Regulation Number: 21 CFR 862.1660 Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: I. Reserved Product Code: JJX Dated: November 14, 2014 Received: November 17, 2014
Dear Kelli Turner:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Katherine Serrano -S
For : Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K143284
Device Name Elecsys Estradiol III CalCheck
Indications for Use (Describe)
For use in the verification of the callbration established by the Elecsys Estradiol III reagent on the indicated Electys and cobas e immunoassay analyzers.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary, Elecsys Estradiol III CalCheck
| Introduction | According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence. | |
|---|---|---|
| Submitter | ||
| name, address, contact | Roche Diagnostics | |
| 9115 Hague Road, P.O. Box 50416 | ||
| Indianapolis, IN 46250-0416 |
Contact Person: Kelli Turner
Phone: 317-521-4515
Fax: 317-521-2324
Email: kelli.turner@roche.com
Secondary Contact: Michael Leuther
Phone: 317-521-3930
Fax: 317-521-2324
Email: michael.leuther@roche.com
Date Prepared: December 12, 2014 | |
| Device Name | Proprietary name:
Common name: | Elecsys Estradiol III CalCheck
Estradiol III CalCheck |
| | Classification: | Class 1, reserved
21 CFR 862.1660, Single (specified) analyte controls (assayed and unassayed) |
| | Product Code: | JJX |
Continued on next page
4
| Device Description | Elecsys Estradiol III CalCheck: The Elecsys Estradiol III CalCheck is a lyophilized product consisting of synthetic Estradiol in a human serum matrix. It has been standardized against CRM6004a via ID-GC/MS (isotope dilution gas chromatography mass spectrometry). |
|---|---|
| Intended use | Elecsys Estradiol III CalCheck: For use in the verification of the calibration established by the Elecsys Estradiol III reagent on the indicated Elecsys and cobas e immunoassay analyzers. |
| Predicate device | The Elecsys Estradiol III CalCheck is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Elecsys CalCheck Estradiol (K970148). |
Continued on next page
5
| Comparison The table below compares Elecsys Estradiol III CalCheck with the predicate | |
|---|---|
| Table | device, Elecsys CalCheck Estradiol (K970148). |
| Characteristic | Elecsys Estradiol III CalCheck
(Candidate) | Elecsys CalCheck Estradiol
(K970148) |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | For use in the verification of the
calibration established by the
Elecsys Estradiol III reagent on
the indicated Elecsys and cobas
e immunoassay analyzers. | The Elecsys CalCheck Estradiol
is for use in the verification of
the calibration established by the
Elecsys Estradiol reagent on the
indicated Elecsys and cobas e
immunoassay analyzers. |
| Analyte | Estradiol (synthetic) | Same |
| Matrix | Human serum matrix | Same |
| Levels | Three | Same |
| Assay
Measuring
Range | 5 - 3000 pg/mL | 5 - 4300 pg/mL |
| Check Target
Values | Check 1: 100 pg/mL
Check 2: 1500 pg/mL
Check 3: 2400 pg/mL | Check 1: 200 pg/mL
Check 2: 2000 pg/mL
Check 3: 4000 pg/mL |
| Format | Lyophilized | Same |
| Handling | Reconstitute Check 1, Check 2,
and Check 3with exactly 1.0 mL
distilled or deionized water.
Allow to stand closed for 15
minutes, then mix gently by
inversion to ensure
homogeneity. | Reconstitute the contents of
Check 1, Check 2 and Check 3
with exactly 1.5 mL distilled or
deionized water. Allow the
bottle to stand closed for 15
minutes. Mix gently by
inversion to ensure
homogeneity. |
| Stability | Unopened:
• Store at 2-8°C until expiration
date
Opened:
• 20-25°C: 4 hours | Unopened:
• Store at 2-8°C until expiration
date
Opened:
• 15-25°C: 4 hours |
Continued on next page
6
| Traceability | The Elecsys Estradiol III CalCheck was standardized against CRM6004a via ID-GC/MS (isotope dilution gas chromatography mass spectrometry). |
|---|---|
| -------------- | -------------------------------------------------------------------------------------------------------------------------------------------- |
| Value Assignment | Value assignment testing was conducted and passed pre-defined acceptance criteria. For each Elecsys Estradiol III CalCheck lot manufactured, the CalChecks are run in duplicate on at least three cobas e 601/MODULAR ANALYTICS E170 analyzers. The assigned value of each CalCheck is defined as the mean value obtained over at least 6 determinations (duplicate runs on at least 3 analyzers) of the respective CalCheck. The CalCheck assigned range is calculated as ±27% of the assigned value for all levels (1, 2 and 3). The label states that each laboratory should establish appropriate acceptance criteria when using this product for its intended use. The same value assignment procedure is performed on the cobas e 411/Elecsys 2010. The assigned values obtained are compared to those obtained on the cobas e 601. The mean value obtained on the additional analyzer must be within 10% of the master platform assigned value. After this acceptance criterion is met, the assigned values from the master platform are deemed valid for the MODULAR ANALYTICS E170, Elecsys 2010, cobas e 411, cobas e 601, and cobas e 602 immunoassay analyzers. | ||
|---|---|---|---|
| Target Values | The CalCheck target values for the Elecsys Estradiol III are as follows: Check Target Values Check 1: 100 pg/mL |
Check 3: 1500 pg/mL
Check 3: 2400 pg/mL | Check Target Values | Check 1: 100 pg/mL
Check 3: 1500 pg/mL
Check 3: 2400 pg/mL |
| Check Target Values | Check 1: 100 pg/mL
Check 3: 1500 pg/mL
Check 3: 2400 pg/mL | | |
Continued on next page
7
Two studies were performed in order to verify the stability claims for the Stability Estradiol III CalCheck. Additionally, a real-time stability study is ongoing to Studies support the shelf-life stability claim.
Opened-vial and accelerated stability studies were completed on the cobas e 411. Because these studies are not analyzer-dependent, these results, in addition to real-time stability study results, can be applied to the Elecsys 2010, MODULAR ANALYTICS E170, cobas e 601 and cobas e 602.
Study 1. Open-Vial Stability:
The on-test and reference materials were tested in duplicate. The on-test material was reconstituted and stored for 6 hours at 25℃ (in an open vial). The reference material was a freshly reconstituted set of CalChecks. The ontest recovery was calculated as a percent of the reference value.
One Estradiol III CalCheck lot was evaluated in duplicate on the cobas e 411. The acceptance criterion for CalCheck Level 1 is 85-115% recovery; and for CalCheck Levels 2-3, the acceptance criterion is recovery of 90-110% recovery of the reference material value.
The data support the package insert claim that reconstituted Estradiol III CalCheck is stable up to 4 hours at 20-25°C.
The CalCheck products are not stored on-board the analyzers, therefore no on-board stability claims are made.
Study 2. Accelerated Stability:
The on-test material was stored lyophilized (as supplied to the user) at 35°C for 3 weeks. The reference material was a freshly reconstituted set of CalChecks (stored at 2-8℃). After 3 weeks, the test and reference materials were tested in duplicate. The on-test recovery was calculated as a percent of the reference value.
One Estradiol III CalCheck lot was evaluated in duplicate on the cobas e 411. The acceptance criterion for CalCheck Level 1 is 85-115% recovery; and for CalCheck Levels 2-3, the acceptance criterion is recovery of 90-110% of the reference material value.
The accelerated stability model employed supports an initial shelf-life claim of 18 months when the Estradiol III CalCheck are stored under normal storage conditions of 2-8°C.
Real-time stability studies are ongoing.
Conclusion We trust that the data and information provided in this Premarket Notification 510(k) submission will support a determination of substantial equivalence for the Elecsys Estradiol III CalCheck.